InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | 2026-04-28 | ORBIMED ADVISORS LLC | 10% Owner | Purchase | 597.7K | $1.67 | $998K | 1.20M | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $2.8M+1134.5% | $226K+0.0% | $226K+0.0% | $226K |
| Acquired in-process research and development | $117.5M | — | — | — |
| Research and development | $12.1M-5.5% | $12.8M+12.4% | $11.4M+0.2% | $11.4M |
| General and administrative | $8.5M-30.7% | $12.3M+35.1% | $9.1M+7.7% | $8.4M |
| Total operating expenses | $20.7M-85.5% | $142.6M+594.8% | $20.5M+3.4% | $19.9M |
| Loss from operations | -$17.9M+87.4% | -$142.4M-601.4% | -$20.3M-3.4% | -$19.6M |
| Change in fair value of warrant liability /Series A warrant and pre-funded warrant expense | $26.6M+208.7% | -$24.4M | — | — |
| Other income, net | $478K+65.4% | $289K-78.6% | $1.4M+103.6% | $663K |
| Net income (loss) | $9.2M+105.5% | -$166.5M-778.8% | -$18.9M | — |
| Net income (loss) attributable to common stockholders, basic | $6.9M+112.6% | -$54.7M-188.5% | -$18.9M | — |
| Net income (loss) attributable to common stockholders, diluted | $6.9M+112.6% | -$54.7M-188.5% | -$18.9M | — |
| Weighted-average shares of common stock outstanding, basic (in shares) | $8.2M+429.9% | $1.6M+84.9% | $840K-96.0% | $20.9M |
| Net income (loss) per share of common stock, basic (in dollars per share) | $0.83+102.4% | -$35.21-56.0% | -$22.57-2380.2% | -$0.91 |
| Weighted-average shares of common stock outstanding, diluted (in shares) | $8.4M+439.5% | $1.6M+84.9% | $840K-96.0% | $20.9M |
| Net income (loss) per share of common stock, diluted (in dollars per share) | $0.82+102.3% | -$35.21-56.0% | -$22.57-2380.2% | -$0.91 |
| Net income (loss) attributable to Series C Preferred stockholders, basic | $2.3M+102.1% | -$111.8M | — | — |
| Net income (loss) attributable to Series C Preferred stockholders, diluted | $2.3M+102.1% | -$111.8M | — | — |
| Weighted-average shares of Series C Preferred outstanding, basic (in shares) | $7K-13.0% | $8K | — | — |
| Weighted-average shares of Series C Preferred outstanding, diluted (in shares) | $7K-13.0% | $8K | — | — |
| Net income (loss) per share of Series C Preferred, basic (in dollars per share) | $333.77+102.4% | -$14K | — | — |
| Net income (loss) per share of Series C Preferred, diluted (in dollars per share) | $333.77+102.4% | -$14K | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Sector Update: Healthcare Stocks Lower Late Afternoon
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Traws Pharma, Inc. Q4 2025 Earnings Call Summary